Baseline characteristics
| . | SSPE . | Proximal PE* . | PE ruled out . | P value . | P value . |
|---|---|---|---|---|---|
| (n = 116) . | (n = 632) . | (n = 2980) . | SSPE vs proximal PE . | SSPE vs PE ruled out . | |
| Age, mean ± SD | 56 ± 17 | 57 ± 18 | 52 ± 18 | .46 | .02 |
| Age >60, n (%) | 50 (43.1) | 301 (47.6) | 1004 (33.7) | .37 | .04 |
| Male sex, n (%) | 64 (55.2) | 309 (48.9) | 1212 (40.7) | .23 | .002 |
| Outpatients, n (%) | 87 (75) | 496 (78.5) | 2431 (81.6) | .41 | .07 |
| VTE risk factors | |||||
| Immobilization, n (%) | 20 (17.2) | 108 (17.1) | 273 (9.2) | .97 | .004 |
| Paralysis, pareses, or recent leg plaster, n (%) | 5 (4.3%) | 37 (5.9%) | 63 (2.1) | .51 | .11 |
| Previous VTE, n (%) | 17 (14.7) | 128 (20.3) | 395 (13.3) | .16 | .66 |
| Recent surgery, n (%) | 15 (12.9) | 72 (11.4) | 155 (5.2) | .64 | <.001 |
| Active malignancy, n (%) | 21 (18.1) | 113 (17.9) | 347 (11.6) | .95 | .04 |
| Estrogen use, women, n (%) | 15 (30.0) | 93 (29.2) | 360 (20.7) | .91 | <.001 |
| Clinical signs and symptoms | |||||
| Duration of complaints, d (median, range) | 2 (0-90) | 3 (0-90) | 2 (0-120) | NA | NA |
| Suspected DVT, n (%) | 10 (8.6) | 81 (12.8) | 90 (3.0) | .08 | .002 |
| Hemoptysis, n (%) | 10 (8.6) | 41 (6.5) | 100 (3.4) | .65 | .03 |
| Clinical probability (Wells score11 ) | |||||
| Unlikely, n (%) | 58 (50) | 244 (38.6) | 2179 (73.1) | .02 | <.001 |
| Likely, n (%) | 58 (50) | 388 (61.4) | 800 (26.9) | ||
| Comorbidities | |||||
| COPD, n (%) | 11 (9.5) | 55 (8.7) | 337 (11.3) | .78 | .55 |
| Heart failure, n (%) | 10 (8.6) | 30 (4.7) | 234 (7.9) | .09 | .75 |
| . | SSPE . | Proximal PE* . | PE ruled out . | P value . | P value . |
|---|---|---|---|---|---|
| (n = 116) . | (n = 632) . | (n = 2980) . | SSPE vs proximal PE . | SSPE vs PE ruled out . | |
| Age, mean ± SD | 56 ± 17 | 57 ± 18 | 52 ± 18 | .46 | .02 |
| Age >60, n (%) | 50 (43.1) | 301 (47.6) | 1004 (33.7) | .37 | .04 |
| Male sex, n (%) | 64 (55.2) | 309 (48.9) | 1212 (40.7) | .23 | .002 |
| Outpatients, n (%) | 87 (75) | 496 (78.5) | 2431 (81.6) | .41 | .07 |
| VTE risk factors | |||||
| Immobilization, n (%) | 20 (17.2) | 108 (17.1) | 273 (9.2) | .97 | .004 |
| Paralysis, pareses, or recent leg plaster, n (%) | 5 (4.3%) | 37 (5.9%) | 63 (2.1) | .51 | .11 |
| Previous VTE, n (%) | 17 (14.7) | 128 (20.3) | 395 (13.3) | .16 | .66 |
| Recent surgery, n (%) | 15 (12.9) | 72 (11.4) | 155 (5.2) | .64 | <.001 |
| Active malignancy, n (%) | 21 (18.1) | 113 (17.9) | 347 (11.6) | .95 | .04 |
| Estrogen use, women, n (%) | 15 (30.0) | 93 (29.2) | 360 (20.7) | .91 | <.001 |
| Clinical signs and symptoms | |||||
| Duration of complaints, d (median, range) | 2 (0-90) | 3 (0-90) | 2 (0-120) | NA | NA |
| Suspected DVT, n (%) | 10 (8.6) | 81 (12.8) | 90 (3.0) | .08 | .002 |
| Hemoptysis, n (%) | 10 (8.6) | 41 (6.5) | 100 (3.4) | .65 | .03 |
| Clinical probability (Wells score11 ) | |||||
| Unlikely, n (%) | 58 (50) | 244 (38.6) | 2179 (73.1) | .02 | <.001 |
| Likely, n (%) | 58 (50) | 388 (61.4) | 800 (26.9) | ||
| Comorbidities | |||||
| COPD, n (%) | 11 (9.5) | 55 (8.7) | 337 (11.3) | .78 | .55 |
| Heart failure, n (%) | 10 (8.6) | 30 (4.7) | 234 (7.9) | .09 | .75 |
SD, standard deviation.
Defined as PE localized in a segmental or central pulmonary artery.